Advanced Cardiac Markers Most Doctors Don’t Order
If you’ve had a physical in the last ten years, you’ve probably been told your cholesterol is “fine.” Your total cholesterol, LDL, HDL, and triglycerides came back within range, and that was the end of the conversation.
The problem is that a standard lipid panel — the one your insurance covers and your doctor orders by default — is a screening tool from the 1980s. It measures the amount of cholesterol in your blood, but it tells you almost nothing about the particles carrying it. And it’s the particles that drive atherosclerotic disease.
We’ve seen this pattern repeatedly in our executive health practice: a patient with fifteen years of “normal” cholesterol panels who, on advanced testing, turns out to have significant cardiovascular risk that no one has ever identified. The standard test didn’t fail. It was never designed to look this deeply.
Why Standard Cholesterol Panels Fall Short
A standard lipid panel reports LDL cholesterol as a single number — say, 120 mg/dL. That number represents the total amount of cholesterol carried in your LDL particles. What it doesn’t tell you is how many particles are carrying it, or what size they are.
This distinction matters enormously. Two patients can have identical LDL cholesterol numbers, but one has a small number of large, buoyant particles (lower risk) while the other has a large number of small, dense particles (significantly higher risk). The small dense particles penetrate arterial walls more easily and are more prone to oxidation — the process that initiates plaque formation. These two patients have the same LDL number but very different cardiovascular trajectories.
A standard panel cannot distinguish between them.
NMR Lipoprofile: Particle Number and Size
The NMR (Nuclear Magnetic Resonance) lipoprofile measures LDL particle number (LDL-P) and particle size directly. Instead of asking “how much cholesterol is in your LDL?” it asks “how many LDL particles do you have, and what size are they?”
LDL particle number is a stronger predictor of cardiovascular events than LDL cholesterol. A patient with a “normal” LDL-C of 110 but an elevated LDL-P of 1,800 has meaningfully higher risk than that LDL-C number suggests. The NMR also identifies Pattern B — a predominance of small dense LDL particles — which is associated with a two- to threefold increase in cardiovascular risk.
We include NMR lipoprofile testing in every executive health evaluation. In our experience, roughly a third of patients with “normal” standard panels have significant particle number or pattern abnormalities.
Lp(a): The Genetic Risk Factor No One Tests
Lipoprotein(a), or Lp(a), is a genetically determined lipoprotein particle that independently increases cardiovascular risk. It promotes clot formation, accelerates plaque growth, and is present from birth at a level that doesn’t change significantly over your lifetime.
Approximately 20% of the population has elevated Lp(a). It’s responsible for an estimated 15–25% of cardiovascular events. And yet it’s almost never tested in routine medical care. Most patients with elevated Lp(a) have no idea they carry this risk factor — because the test isn’t part of a standard panel.
Lp(a) only needs to be measured once in your lifetime, since it’s genetically fixed. But that single measurement can fundamentally change your risk stratification and treatment plan — particularly in combination with other findings like LDL particle abnormalities or a family history that wasn’t previously explained by standard testing.
ApoB: A Single Number for Atherogenic Particle Burden
Apolipoprotein B (ApoB) is a protein found on every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a). Because each particle carries exactly one ApoB molecule, the ApoB level is essentially a count of all the particles in your blood that can contribute to plaque formation.
Many cardiologists now consider ApoB the single best metric for assessing cardiovascular risk from lipoproteins. It integrates the information from LDL-C, triglycerides, and particle number into a single value. An elevated ApoB in the setting of “normal” LDL-C is a red flag that standard testing would miss entirely.
Beyond Lipids: hs-CRP and Inflammatory Markers
Cardiovascular disease is, at its core, an inflammatory process. Plaque doesn’t just accumulate — it inflames, destabilizes, and ruptures. High-sensitivity C-reactive protein (hs-CRP) measures systemic inflammation and has been shown to independently predict cardiovascular events, even in patients with normal cholesterol.
We routinely include hs-CRP and other inflammatory markers in our panels. In isolation, a mildly elevated hs-CRP might not change management. But when combined with an elevated LDL particle number, a high Lp(a), or a non-zero coronary calcium score, it becomes one more data point in a risk profile that demands attention.
The Imaging Connection: Coronary Calcium Score and CIMT
Advanced labs are powerful, but they measure risk factors — not disease. To assess whether atherosclerosis has actually begun, we pair lab testing with direct imaging: a CT coronary calcium score that quantifies calcified plaque in the coronary arteries, and a carotid intima-media thickness (CIMT) ultrasound that measures the earliest structural changes in your arterial walls.
A non-zero calcium score in a patient with elevated LDL-P and Lp(a) changes the clinical picture dramatically. It’s the difference between “you have risk factors” and “there is already disease.” This combination — advanced biomarkers plus vascular imaging — is what allows us to find cardiovascular disease in asymptomatic patients who look perfectly healthy on standard screening.
Why These Tests Aren’t Standard
The honest answer is cost and system design. Insurance-based medicine is optimized for population-level screening at the lowest cost. Standard lipid panels are inexpensive, widely available, and “good enough” for most guideline-based care. NMR lipoprofiles, Lp(a), and coronary calcium scores add cost that insurance companies don’t consider justified for asymptomatic patients — even though the data clearly shows they identify risk that standard testing misses.
For executives and high-performing professionals whose health is genuinely their most important asset, “good enough” screening isn’t the standard they’d accept in any other area of their lives. Understanding your actual cardiovascular risk — not the simplified version your insurance will pay for — is one of the things that makes a comprehensive executive health evaluation different from an annual physical.
Our executive health evaluation includes all of these markers as part of the standard panel. If you want to know where you actually stand, contact us or call (415) 963-4431.
